vs

Side-by-side financial comparison of ASPEN AEROGELS INC (ASPN) and ARS Pharmaceuticals, Inc. (SPRY). Click either name above to swap in a different company.

ASPEN AEROGELS INC is the larger business by last-quarter revenue ($41.3M vs $28.1M, roughly 1.5× ARS Pharmaceuticals, Inc.). ARS Pharmaceuticals, Inc. runs the higher net margin — -147.1% vs -176.4%, a 29.2% gap on every dollar of revenue. On growth, ASPEN AEROGELS INC posted the faster year-over-year revenue change (-66.4% vs -67.6%).

Aspen Aerogels Inc is a leading manufacturer of high-performance aerogel-based insulation and thermal management materials. It serves core sectors including renewable energy, oil and gas infrastructure, aerospace, commercial construction and industrial manufacturing, with key markets across North America, Europe and Asia-Pacific. Its products are prized for superior thermal resistance, fire safety and lightweight performance for harsh operating conditions.

ARS Pharmaceuticals, Inc. is a late-stage biopharmaceutical firm specializing in the development and commercialization of novel therapies for severe allergic reactions, most notably needle-free epinephrine delivery solutions for anaphylaxis. It primarily operates in the North American market, catering to both pediatric and adult patient groups at risk of life-threatening allergic responses.

ASPN vs SPRY — Head-to-Head

Bigger by revenue
ASPN
ASPN
1.5× larger
ASPN
$41.3M
$28.1M
SPRY
Growing faster (revenue YoY)
ASPN
ASPN
+1.1% gap
ASPN
-66.4%
-67.6%
SPRY
Higher net margin
SPRY
SPRY
29.2% more per $
SPRY
-147.1%
-176.4%
ASPN

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ASPN
ASPN
SPRY
SPRY
Revenue
$41.3M
$28.1M
Net Profit
$-72.9M
$-41.3M
Gross Margin
-55.5%
Operating Margin
-170.3%
-147.6%
Net Margin
-176.4%
-147.1%
Revenue YoY
-66.4%
-67.6%
Net Profit YoY
-741.7%
-182.8%
EPS (diluted)
$-0.87
$-0.41

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASPN
ASPN
SPRY
SPRY
Q4 25
$41.3M
$28.1M
Q3 25
$73.0M
$32.5M
Q2 25
$78.0M
$15.7M
Q1 25
$78.7M
$8.0M
Q4 24
$123.1M
$86.6M
Q3 24
$117.3M
$2.1M
Q2 24
$117.8M
$500.0K
Q1 24
$94.5M
$0
Net Profit
ASPN
ASPN
SPRY
SPRY
Q4 25
$-72.9M
$-41.3M
Q3 25
$-6.3M
$-51.2M
Q2 25
$-9.1M
$-44.9M
Q1 25
$-301.2M
$-33.9M
Q4 24
$11.4M
$49.9M
Q3 24
$-13.0M
$-19.1M
Q2 24
$16.8M
$-12.5M
Q1 24
$-1.8M
$-10.3M
Gross Margin
ASPN
ASPN
SPRY
SPRY
Q4 25
-55.5%
Q3 25
28.5%
Q2 25
32.4%
Q1 25
29.0%
Q4 24
38.3%
Q3 24
41.8%
Q2 24
43.8%
Q1 24
37.2%
Operating Margin
ASPN
ASPN
SPRY
SPRY
Q4 25
-170.3%
-147.6%
Q3 25
-4.6%
-163.7%
Q2 25
-6.6%
-302.9%
Q1 25
-380.2%
-466.3%
Q4 24
12.0%
54.5%
Q3 24
14.8%
-1051.6%
Q2 24
17.0%
-3068.0%
Q1 24
2.6%
Net Margin
ASPN
ASPN
SPRY
SPRY
Q4 25
-176.4%
-147.1%
Q3 25
-8.7%
-157.4%
Q2 25
-11.6%
-285.6%
Q1 25
-382.7%
-425.7%
Q4 24
9.2%
57.7%
Q3 24
-11.1%
-925.0%
Q2 24
14.3%
-2503.2%
Q1 24
-1.9%
EPS (diluted)
ASPN
ASPN
SPRY
SPRY
Q4 25
$-0.87
$-0.41
Q3 25
$-0.08
$-0.52
Q2 25
$-0.11
$-0.46
Q1 25
$-3.67
$-0.35
Q4 24
$0.15
$0.52
Q3 24
$-0.17
$-0.20
Q2 24
$0.21
$-0.13
Q1 24
$-0.02
$-0.11

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASPN
ASPN
SPRY
SPRY
Cash + ST InvestmentsLiquidity on hand
$156.9M
$245.0M
Total DebtLower is stronger
$65.5M
$96.4M
Stockholders' EquityBook value
$235.5M
$114.3M
Total Assets
$406.7M
$327.7M
Debt / EquityLower = less leverage
0.28×
0.84×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASPN
ASPN
SPRY
SPRY
Q4 25
$156.9M
$245.0M
Q3 25
$150.7M
$288.2M
Q2 25
$167.6M
$240.1M
Q1 25
$192.0M
$275.7M
Q4 24
$220.9M
$314.0M
Q3 24
$113.5M
$204.6M
Q2 24
$91.4M
$218.7M
Q1 24
$101.5M
$223.6M
Total Debt
ASPN
ASPN
SPRY
SPRY
Q4 25
$65.5M
$96.4M
Q3 25
$70.1M
$96.2M
Q2 25
$77.3M
Q1 25
$95.4M
Q4 24
$95.0M
$0
Q3 24
$93.7M
Q2 24
Q1 24
Stockholders' Equity
ASPN
ASPN
SPRY
SPRY
Q4 25
$235.5M
$114.3M
Q3 25
$305.7M
$147.7M
Q2 25
$308.8M
$192.3M
Q1 25
$314.8M
$229.0M
Q4 24
$614.7M
$256.8M
Q3 24
$507.6M
$201.0M
Q2 24
$517.8M
$215.2M
Q1 24
$491.2M
$223.9M
Total Assets
ASPN
ASPN
SPRY
SPRY
Q4 25
$406.7M
$327.7M
Q3 25
$491.4M
$372.8M
Q2 25
$525.1M
$313.5M
Q1 25
$555.0M
$327.3M
Q4 24
$895.1M
$351.2M
Q3 24
$782.6M
$217.6M
Q2 24
$748.6M
$222.0M
Q1 24
$698.0M
$227.6M
Debt / Equity
ASPN
ASPN
SPRY
SPRY
Q4 25
0.28×
0.84×
Q3 25
0.23×
0.65×
Q2 25
0.25×
Q1 25
0.30×
Q4 24
0.15×
0.00×
Q3 24
0.18×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASPN
ASPN
SPRY
SPRY
Operating Cash FlowLast quarter
$16.1M
$-43.5M
Free Cash FlowOCF − Capex
$13.7M
FCF MarginFCF / Revenue
33.1%
Capex IntensityCapex / Revenue
6.0%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-4.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASPN
ASPN
SPRY
SPRY
Q4 25
$16.1M
$-43.5M
Q3 25
$15.0M
$-47.0M
Q2 25
$-3.9M
$-39.6M
Q1 25
$5.6M
$-40.7M
Q4 24
$35.7M
$42.0M
Q3 24
$20.8M
$-14.5M
Q2 24
$6.8M
$-7.3M
Q1 24
$-17.7M
$-6.7M
Free Cash Flow
ASPN
ASPN
SPRY
SPRY
Q4 25
$13.7M
Q3 25
$5.9M
$-47.2M
Q2 25
$-16.8M
$-39.6M
Q1 25
$-7.4M
$-40.8M
Q4 24
$20.9M
$41.7M
Q3 24
$-50.0K
$-14.6M
Q2 24
$-18.0M
$-7.3M
Q1 24
$-43.6M
$-6.8M
FCF Margin
ASPN
ASPN
SPRY
SPRY
Q4 25
33.1%
Q3 25
8.1%
-145.4%
Q2 25
-21.6%
-252.2%
Q1 25
-9.4%
-512.1%
Q4 24
17.0%
48.2%
Q3 24
-0.0%
-706.3%
Q2 24
-15.3%
-1463.4%
Q1 24
-46.1%
Capex Intensity
ASPN
ASPN
SPRY
SPRY
Q4 25
6.0%
0.0%
Q3 25
12.5%
0.6%
Q2 25
16.5%
0.3%
Q1 25
16.5%
1.1%
Q4 24
12.0%
0.3%
Q3 24
17.7%
6.8%
Q2 24
21.1%
7.6%
Q1 24
27.4%
Cash Conversion
ASPN
ASPN
SPRY
SPRY
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
3.14×
0.84×
Q3 24
Q2 24
0.41×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASPN
ASPN

Energy Industrial$14.5M35%
Other$13.9M34%
Thermal Barrier$12.9M31%

SPRY
SPRY

Products$20.3M72%
Other$7.8M28%

Related Comparisons